Lung Metastasectomy from Colorectal Cancer, 10-year Experience in a South American Cancer Center

Carlos Carvajal*, Helena Facundo, Paola Puerto, José Carreño and Rafael Beltrán

*Thoracic Surgery, National Cancer Institute, Bogota, Colombia, †Gastro-intestinal surgery, National Cancer Institute, Bogota, Colombia, ‡Oncologic surgery, National Cancer Institute, Bogota, Colombia, §Research Department, National Cancer Institute, Bogota, Colombia

Purpose: This study aimed to describe the survival outcomes and factors associated with prognosis in patients undergoing pulmonary metastasectomy with colorectal cancer (CRC) in a cancer center in South America.

Material and methods: A retrospective analysis of patients that underwent lung metastasectomy due to CRC at National Cancer Institute (INC), Colombia between 2007 and 2017 was performed and Kaplan-Meier survival analysis along with log-rank test and Cox regression multivariate analysis were completed.

Results: Seventy-five patients with colorectal adenocarcinoma were included in the study. Of them, 57.3% were women with a median age of 62 years [interquartile ranges (IQR): 18.5]. For 45.3% the adenocarcinoma was located in the rectum and 29.3% had stage IV at diagnosis. 56% had a history of controlled extrapulmonary metastasis and 20% of the cases had a history of the metastasis of the liver. The median follow-up was 36.8 months (IQR: 27.4). Three-year and five-year overall survival (OS) was 57.5% [95% confidence interval (CI), 47.0–70.4] and 33.2% (95% CI, 23.4–47.2), respectively. Patients with bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy carcinoembryonic antigen (CEA), history of liver metastasis, and disease-free interval (DFI) ≤12 months had worse OS. Three-year and five-year disease-free survival (DFS) was 30.1% (95% CI, 20.8–43.6) and 21.6% (95% CI, 13.0–35.9), respectively. Bilateral, more than one pulmonary metastasis, and patients with stage IV at diagnosis had the worst DFS. Multivariate analysis in the Cox regression model showed that abnormal postmetastasectomy CEA [Hazard Ratio (HR):1.97, 95% CI, 1.01–3.86, p = 0.045] and DFI ≤12 months (HR: 3.08, 95% CI, 1.26–7.53, p = 0.014) were independent factors for worst OS.

Conclusions: The OS found falls within the wide range described in the world literature but interestingly it falls at the bottom end of this range. The factors associated with worst survival were identified as bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy CEA, history of liver metastasis, and DFI ≤12 months.
**Contribution to the field:** Pulmonary metastasectomy is the standard of care in patients with metastatic CRC. However, the literature supporting this conduct is based on retrospective studies and the only randomized controlled trial conducted to date was stopped due to poor recruitment. Limited information is available in South America about survival and factors associated with prognosis in patients with metastatic CRC. While this study is another series that adds to the many studies across the world that describe the use of pulmonary metastasectomy in CRC, it presents critical data as it is one of the few studies carried out in South America. As described in a wide range of world literature, OS found falls in patients that underwent lung metastasectomy due to CRC however; interestingly, in the South American population analyzed here it falls at the bottom end of this range. This may be explained by a large number of patients included with a history of extrapulmonary metastasis as well as may reflect inadequate patient access to reference cancer centers in Colombia. Factors associated with worst survival in our population were bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy CEA, history of liver metastasis, and interval from diagnosis to development of pulmonary metastasis ≤12 months.

**Keywords:** metastasectomy, colorectal neoplasms, neoplasm metastasis, multiple pulmonary nodules, solitary pulmonary nodule

---

**INTRODUCTION**

Based on the estimated new cancer cases for 2022, colorectal cancer (CRC) is the second highest cause of cancer deaths in the United States and the third most frequently occurring cancer in women and men (1). The lung is the second most common site of metastasis in patients with CRC. Although rectal cancer has a higher incidence of lung spread than colon cancer, nearly 20% of patients with CRC will develop lung metastasis (2).

General indications for pulmonary metastasectomy also apply for metastasectomy in CRC. These include adequate cardiopulmonary reserve that allows resection, controlled primary tumor, completely resectable lung metastases, no other effective treatment other than resection, and no extrapulmonary metastatic disease, or if present, controllable by surgery or other local therapy (3). Pulmonary metastasectomy has been generally accepted as a potentially curative option in the management of metastatic CRC. When metastasectomy is not feasible, the main treatment methods are chemotherapy and targeted therapy (4). The five-year survival rates of patients with metastatic CRC who receive only supportive care are less than 5%, while a systematic review and meta-analysis including 25 non-randomized studies published between 2000 and 2011, reported a five-year survival after complete resection between 27%–68% for pulmonary metastasectomy (5).

Limited information is available in South America about the role of pulmonary metastasectomy in metastatic CRC. Therefore, this study aimed to describe the survival outcomes and factors associated with prognosis in patients undergoing pulmonary metastasectomy with CRC in a cancer center in South America.

**MATERIALS AND METHODS**

We conducted a retrospective analysis of patients that underwent lung metastasectomy from colorectal cancer at the National Cancer Institute (INC), Colombia between December 1, 2007, and November 30, 2017. Exclusion criteria included patients with an uncontrolled extrapulmonary disease or who received other pulmonary local treatment modalities such as radiofrequency ablation or stereotactic radiotherapy. Medical records of all eligible patients were reviewed. This included evaluating demographic and histopathological data, characteristics of the primary tumor, staging, levels of carcinoembryonic antigen (CEA), characteristics of pulmonary metastases, surgical procedure, complications, and outcomes. Data were collected using the RedCap 7.1.2 platform.

Overall survival (OS) was calculated from the date of pulmonary metastasectomy until death or the last contact at the INC. Disease-free survival (DFS) was calculated from the date of the first pulmonary metastasectomy until documentation of disease recurrence by imaging or histopathologic confirmation. Disease-free interval (DFI) was calculated from the date of surgical management of the primary CRC until the date of the pulmonary metastasectomy. The normal serum CEA concentration range was 0–5 ng/mL. CEA prior to metastasectomy was performed up to six months before pulmonary metastasectomy and postmetastasectomy CEA was performed up to six months after. Numerical variables were presented in medians and interquartile ranges (IQR), while the categorical variables were presented in absolute values and percentages. Chi-square test was used to find associations between categorical variables and Wilcoxon signed-rank test for quantitative variables. Survival curves were performed using the
RESULTS

Between 2007 and 2017, 75 patients underwent pulmonary metastasectomy from CRC, of which 43 (57.3%) were women and the median age was 62 years (IQR: 18.5). Regarding the characteristics of the primary tumor, 80.0% of the cases were usual adenocarcinoma, followed by mucinous adenocarcinoma in 17.3% and Signet-ring cell adenocarcinoma in 2.7%; half of the patients included were stage III (53.3%) and 29.3% had stage IV at diagnosis (Table 1). A moderate degree of differentiation was described in 62.7% of the patients and the most frequent location was the rectum (45.3%); Thirty (40%) patients had more than one pulmonary metastasis. The liver being the most frequent location (20.0%), followed by peritoneum (13.3%) and retroperitoneum (6.7%) (Table 1). PET-CT was not a routine procedure before pulmonary metastasectomy in CRC, in our service.

Mutation analysis was performed in 63 (84.0%) patients. Of these, the most frequent mutation was Kirsten rat sarcoma virus (K-RAS) in 55.5%, including two patients with K-RAS and Neuroblastoma rat sarcoma virus (N-RAS) mutations (Table 1).

In our series, 42 (56.0%) patients underwent one surgical lung procedure, 26 (34.7%) two procedures, and seven (9.3%) three or four procedures (Table 1). A total of 117 surgical procedures were performed on these 75 patients. Wedge resection was the main pulmonary resection performed in all surgical procedures, corresponding to 70.1%, followed by lobectomy in 13.7%. Video-assisted thoracoscopic surgery (VATS) was the approach in 91 procedures (77.8%), of which 65.9% were uniporal VATS and 34.1% were multiportal VATS; conversion rate was 5.5%. A mediastinal lymph node sample was performed in 17.3% of patients, and only two patients (2.7%) were positive for metastasis. Meanwhile, a hilar lymph node sample was performed in 8.0% of patients and only one patient presented tumor involvement. A pulmonary artery injury was the only intraoperative complication described during a lobectomy, there was no intraoperative mortality and the postoperative complication rate was 5.1%. Regarding the systemic treatment of the primary CRC, 94.7% of patients received chemotherapy: neoadjuvant in 5.30%, adjuvant in 58.7%, and neoadjuvant/adjuvant in 30.7%. The median DFI was 25.6 months (IQR: 25.1).

The median follow-up was 36.8 months (IQR: 27.4) and 50 (66.7%) patients died during this period. Three-year and 5-year OS was 40.4 months (95% CI, 35.1–48.8) (Figure 1A).

The Kaplan-Meier curves showed that patients with bilateral (p = 0.0022), more than one pulmonary metastasis (p = 0.0009), abnormal postmetastasectomy CEA (p = 0.0009), history of liver metastasis (p = 0.0170) and DFI ≤ 12 months (p = 0.0001) had a worse OS (Figures 1B–F) and these differences were statistically significant (p < 0.01) (Table 3).

Multivariate analysis showed that DFI ≤ 12 months (HR: 3.08, 95% CI, 1.26–7.53, p = 0.014) and abnormal postmetastasectomy CEA (HR: 1.97, 95% CI, 1.01–3.86, p = 0.045) were independent factors for worst overall survival (Table 4).

On the other hand, 53 (70.7%) patients presented disease recurrence during the follow-up period. Three-year and five-year DFS was 30.1% (95% CI, 20.8–43.6) and 21.6% (95% CI, 13.0–35.9), respectively. The median DFS was 24.6 months (95% CI, 18.5–28.6) (Figure 2A). Bilateral, more than one
pulmonary metastasis, and patients with stage IV at diagnosis had the worst DFS (Figures 2B–D) (Table 3). There was no association between DFI ≤ 12 months and recurrence (p = 0.559).

**DISCUSSION**

Several retrospective studies support the use of pulmonary metastasectomy as a standard of care in metastatic CRC (6) but some do not show clear survival benefits at present (7). Our study found a five-year OS of 33.2%, which is within the range of OS in such cases described in the literature (27%–68%) (5). Nevertheless, it is far from the 49.8% found by Gössling in Brazil (8) and even further from the 68.1% described by Okumura in Japan (9). Our OS was similar to that reported in the PulMiCC trial (NCT01106261), the only randomized controlled trial to date comparing pulmonary metastasectomy with systemic therapy, which reported a 38% five-year survival for metastasectomy and was stopped due to poor recruitment (10).

As described in a 2013 metaanalysis, short DFI is one of the most important factors of worst prognosis in pulmonary metastasectomy in CRC, as it was associated with an increased risk of death (HR: 1.59, 95% CI, 1.27–1.98) (5). In our series, we found an association between DFI ≤ 12 months and worst OS (HR: 3.08, 95% CI, 1.26–7.53, p = 0.014) in the multivariate analysis.

| TABLE 2 | Association between variables and death. |
|-------------------------------------------------|
| Variables                                      | Total (n = 75) | Death (n = 50) | Alive (n = 25) | p-valuea |
| Degree of differentiation, n (%)               |               |               |               |          |
| Well                                           | 20 (26.7)     | 14 (28.0)     | 6 (24.0)      | 0.233    |
| Moderate                                       | 47 (62.7)     | 30 (60.0)     | 17 (68.0)     |          |
| Poor                                           | 5 (6.6)       | 5 (10.0)      | 0 (0.00)      |          |
| No data                                        | 3 (4.0)       | 1 (2.00)      | 2 (8.00)      |          |
| Localization, n (%)                            |               |               |               |          |
| Ascending colon                                | 16 (21.4)     | 9 (18.0)      | 7 (28.0)      | 0.595    |
| Descending colon                               | 25 (33.3)     | 17 (34.0)     | 8 (32.0)      |          |
| Rectum                                         | 34 (45.3)     | 24 (48.0)     | 10 (40.0)     |          |
| CEAb prior to metastasectomy                   | Median [IQR]  | 3.59 [5.60]   | 4.40 [6.60]   | 0.154d   |
| Postmetastasectomy CEA                         | Median [IQR]  | 3.72 [8.72]   | 7.98 [15.5]   | <0.01d   |
| Pulmonary metastasis, n (%)                    |               |               |               |          |
| Unilateral                                     | 39 (52.0)     | 22 (44.0)     | 17 (68.0)     | 0.048    |
| Bilateral                                      | 36 (48.0)     | 28 (56.0)     | 8 (32.0)      |          |
| Size of metastases, n (%)                      | Median [IQR]  | 10.7 [9.50]   | 10.4 [8.75]   | 0.513    |
| Number of pulmonary metastases, n (%)          |               |               |               |          |
| 1                                              | 44 (58.7)     | 26 (52.0)     | 18 (72.0)     | <0.01    |
| 2–3                                           | 23 (30.7)     | 18 (36.0)     | 5 (20.0)      |          |
| >3                                            | 7 (9.30)      | 5 (10.0)      | 2 (8.00)      |          |
| No data                                        | 1 (1.30)      | 1 (2.00)      | 0 (0.00)      |          |
| Number of pulmonary procedures, n (%)          |               |               |               |          |
| 1                                              | 42 (56.0)     | 27 (54.0)     | 15 (60.0)     | 0.666    |
| 2                                              | 26 (34.7)     | 19 (38.0)     | 7 (28.0)      |          |
| 3–4                                           | 7 (9.30)      | 4 (8.00)      | 3 (12.0)      |          |
| Disease free survival                          |               |               |               |          |
| ≤12 months                                     | 17 (22.7)     | 15 (30.0)     | 2 (8.00)      | 0.032    |
| >12 months                                     | 58 (77.3)     | 35 (70.0)     | 23 (92.0)     |          |
| Chemotherapy, n (%)                            |               |               |               |          |
| Yes                                            | 71 (94.7)     | 47 (94.0)     | 24 (96.0)     | 1.00     |
| No                                             | 4 (5.30)      | 3 (6.00)      | 1 (4.00)      |          |

aChi square test.
bCEA: carcinoembryonic antigen.
cIQR: interquartile range.
dWilcoxon signed-rank test.
eLargest diameter of the biggest metastasis.
Fukada et al. (14) described that CEA before metastasectomy, in the univariate analysis, was one of the seven significant factors related to survival. In our series, we did not find an association between survival and CEA before metastasectomy but we did find an association in the univariate and multivariate analysis between worst OS and abnormal postmetastasectomy CEA (HR: 1.97, 95% CI, 1.01–3.86, \( p = 0.045 \)). Fukada et al. did not describe postmetastasectomy CEA or its association with survival.

Postmetastasectomy CEA is not a commonly mentioned finding in the literature, probably because few studies are focused on repeated lung resections for metastases and because postmetastasectomy CEA may correspond to CEA before the second procedure in those series where more than one surgery is performed. In our study, 44% of the patients underwent more than one procedure for pulmonary metastasectomy and we did not find an association between the number of procedures and death (\( p = 0.666 \)). Ambrogi et al. (15) described that the lack of guidelines for redo pulmonary metastasectomy and the insignificant increment of perioperative mortality or morbidity, make redo metastasectomy a feasible procedure, especially in patients with metastatic CRC who represent the most common pathology in which redo metastasectomy is performed.

In our series, 20% of the patients had a history of controlled hepatic metastasis before pulmonary metastasectomy. The five-year OS of these patients was 6% and in the univariate analysis, these patients had worst overall survival compared to those patients without extrapulmonary metastasis and even in patients with other controlled extrapulmonary metastasis. Although five-year OS of patients with a history of hepatic metastasectomy before pulmonary metastasectomy ranges from 11 to 65% in the previous series (16, 17) and therefore is strongly recommended, our results were not so encouraging and must be taken into account when deciding to perform pulmonary metastasectomy.

Furthermore, Cho et al. (18) found that patients with multiple pulmonary metastases in CRC were associated with the worst prognosis (HR = 2.121, 95% CI, 1.081–4.159, \( p = 0.029 \)); similar results in the univariate analysis were found in our series where HR = 2.30 (95% CI, 1.08–4.93, \( p = 0.032 \)) was obtained.

Moreover, Socola et al. (19) described that bilateral metastases were found only in 7% of the patients that underwent resection in their retrospective cohort study that included 28 patients with pulmonary metastases managed with surgery and 46 controls managed without surgery. They also described that there was no association between bilateral pulmonary metastasectomy and survival (\( p = 0.717 \)). Likewise, in our series, 48% of our patients had bilateral metastases and in the univariate analysis, we did find that patients with bilateral metastases had the worst overall survival (HR = 2.28, 95% CI, 1.23–4.25, \( p < 0.01 \)).

Mediastinal lymph node metastasis was the main factor of the worst prognosis for survival after pulmonary metastasectomy in CRC found by Hamaji et al. (20) (\( p = 0.047 \) in univariate and \( p = 0.0028 \) in multivariate analysis) and they recommended the use of systematic mediastinal lymph node dissection for...
TABLE 3 | Associations between overall survival, disease-free survival and clinical variables.

| Variables            | Overall Survival % [CI95%] | p-value* |
|----------------------|---------------------------|----------|
|                      | 36 months                 | 60 months|
| Metastasis           |                           |          |
| Unilateral           | 64.8 [51.1–82.2]          | 43.1 [29.2–63.6] | 0.0022 |
| Bilateral            | 49.6 [35.1–70.1]          | 22.2 [11.4–43.7] |          |
| Number of pulmonary metastases |                  |          |
| One                  | 61.9 [48.8–78.6]          | 48.7 [35.4–67.1] | 0.0009 |
| More than one        | 50.6 [35.1–73.1]          | –        |          |
| Postmetastasectomy CEA<sup>b</sup> |                        |          |
| Normal               | 72.4 [59.2–88.6]          | 49.3 [34.6–70.5] | 0.0009 |
| Abnormal             | 38.4 [24.2–60.9]          | 17.5 [7.89–38.7] |          |
| Extrapulmonary metastasis |                        |          |
| Liver                | 41.8 [23.8–73.3]          | 5.96 [0.89–39.8] | 0.0170 |
| Other                | 59.8 [42.6–84.1]          | 44.4 [28.0–71.9] |          |
| None                 | 64.9 [50.1–84.1]          | 44.9 [28.7–68.6] |          |
| Disease free interval| ≤12 months                | 38.8 [21.0–71.9] | <0.01  |
|                      | >12 months                | 62.9 [51.2–77.3] | 41.4 [29.6–67.9] |          |

| Variables            | Disease Free Survival % [CI95%] | p-value* |
|----------------------|---------------------------------|----------|
|                      | 36 months                       | 60 months|
| Metastasis           |                                 |          |
| Unilateral           | 41.1 [27.5–61.7]                | 34.7 [21.9–55.0] | 0.0026 |
| Bilateral            | 18.5 [8.80–38.9]                | 13.8 [5.45–35.3] |          |
| Number of pulmonary metastases |                |          |
| One                  | 58.0 [40.3–83.3]                | 47.4 [30.0–74.9] | 0.0027 |
| More than one        | 16.2 [8.15–32.4]                | 13.5 [6.23–29.5] |          |
| Stage                |                                 |          |
| II and III           | 39.0 [27.4–55.6]                | 27.5 [16.6–45.6] | 0.0048 |
| IV<sup>c</sup>       | 5.91 [0.89–39.3]                | –        |          |

<sup>a</sup>Log-Rank test.
<sup>b</sup>CLEA: carcinoembryonic antigen.
<sup>c</sup>Stage IV at diagnosis.

prognostic purposes. However, in our series, we did not find an association between positive hilar or mediastinal lymph node and worst prognosis. This may be explained by the fact that these are not routine procedures in our hospital practice, mediastinal and hilar lymph node sampling was performed in 17.3% and 8.0% of patients, respectively.

Gössling et al. (8) reported that variables that showed significance with long-term relapse-free survival and OS were longer DFI, large lesion size, number of lesions, metachronous presentation, and CK20 expression in metastases. But it must be noted that laterality and adjuvant or perioperative chemotherapy did not have a statistical impact in their sample. In our series, the variables associated with worst DFS were bilateral metastases, more than one pulmonary metastasis, and patients with stage IV at diagnosis had worst DFS.

The limitations of this study include its retrospective nature and single-center analysis. Medical records had incomplete information on variables such as the degree of differentiation and the number of metastases. Furthermore, complete information about the management of extrapulmonary metastases was not available and mutation analysis was not performed on the total population. Although this study is one more series of many in the world that describes the use of pulmonary metastasectomy in CRC, it presents some interesting insights, as it is one of the few studies that were carried out in South America.

CONCLUSIONS

The overall survival found in this series falls within the wide range described in the world literature however; remarkably it falls at the bottom end of this range. Aspects that we believe contributed to our worse OS when compared to other series are a high number of patients included bilateral, more than one metastasis, and history of extrapulmonary metastasis. These findings may also reflect inadequate access to reference cancer centers in Colombia, a country that belongs to lower- and median-income countries.
Factors associated with worst survival were bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy CEA, history of liver metastasis, and DFI $\leq$ 12 months.

Postmetastasectomy CEA is not a commonly mentioned finding in the literature, probably because few studies are focused on repeated lung resections for metastases and because postmetastasectomy CEA may correspond to CEA before the second procedure in those cases where more than one surgery is performed. These factors associated with the worst prognosis must be taken into account when deciding on the management of patients with metastatic CRC.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics and research committee of the National Cancer Institute, Colombia. (N° CEI-00855-20). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

CC, HF, PP, and RB: study conception and design. CC and PP: collection of clinical data. CC and JC: Statistical analysis. CC, HF, PP, and RB drafted the manuscript. All authors contributed to the article and approved the submitted version.
FUNDING
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. (2022) 72(1):7–33. doi: 10.3322/caac.21708
2. Cho JH, Hamaji M, Allen MS, Cassivi SD, Wigle DA, et al. The prognosis of pulmonary metastasectomy depends on the location of the primary colorectal cancer. Ann Thorac Surg. (2014) 98(4):1231–7. doi: 10.1016/j.athoracsur.2014.05.023
3. Kanazaki R, Fukui E, Kanou T, Ose N, Funaki S, Minami M, et al. Preoperative evaluation and indications for pulmonary metastasectomy. J Thorac Dis. (2021) 13(4):2590–602. doi: 10.21037/jtd-19-3791
4. Zhang H, You J, Liu W, Chen D, Zhang S, Wang X. The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). (2021) 100(30):e26714. doi: 10.1097/MD.0000000000026714
5. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. (2013) 20(2):572–9. doi: 10.1245/s10434-012-2726-3
6. Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. (2019) 107(2):631–49. doi: 10.1016/j.athoracsur.2018.10.028
7. Lee KY, Lau J, Siew BE, Chua YK, Lim YX, Lim XY, et al. Does pulmonary metastasectomy of colorectal cancers translate to better survival? A systematic review. Ann Acad Med Singap. (2021) 50(10):773–81. doi: 10.4170/annals-academmed.2021255
8. Gössling GCL, Chedid MF, Pereira FS, da Silva RK, Andrade LB, Peruzzo N, et al. Outcomes and prognostic factors of patients with metastatic colorectal cancer who underwent pulmonary metastasectomy with curative intent: a Brazilian experience. Oncologist. (2021) 26(9):e1581–8. doi: 10.1002/ongo.13802
9. Okumura T, Boku N, Hishida T, Ohade Y, Sakao Y, Yoshiya K, et al. Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg. (2017) 104(3):979–87. doi: 10.1016/j.athoracsur.2017.03.021
10. Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PuMiCC): a multicentre randomised clinical trial. Trials. (2019) 20(1):718. doi: 10.1186/s13063-019-3837-y
11. Shimizu K, Ohtaki Y, Okumura T, Boku N, Horio H, Takenoyama M, et al. Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases. J Thorac Cardiovasc Surg. (2019) 157(5):2049–57.e1. doi: 10.1016/j.jtcvs.2018.12.075
12. Kim S, Kim HK, Cho JH, Choi YS, Kim K, Kim J, et al. Prognostic factors after pulmonary metastasectomy of colorectal cancers: influence of liver metastasis. World J Surg Oncol. (2016) 14(1):201. doi: 10.1186/s12957-016-0940-3
13. Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J Hematol Oncol. (2019) 12(1):16. doi: 10.1186/s13045-019-0702-0
14. Fukada M, Matushahi N, Takahashi T, Tanaka Y, Okumura N, Yamamoto H, et al. Prognostic factors in pulmonary metastasectomy and efficacy of repeat pulmonary metastasectomy from colorectal cancer. World J Surg Oncol. (2020) 18(1):314. doi: 10.1186/s12957-020-02076-3
15. Ambrogi V, Tamburini A, Tajé R. Results of redo pulmonary metastasectomy. J Thorac Dis. (2021) 13(4):2669–85. doi: 10.21037/jtd-19-4064
16. Zabaleta J, Aguinaagdal B, Fuentes MG, Bazterrargui N, Izquierdo JM, Hernández CJ, et al. Survival after lung metastasectomy for colorectal cancer: importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol. (2011) 37(9):786–90. doi: 10.1016/j.ejso.2011.05.014
17. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Druceux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. (1998) 66(1):214–8; discussion 218–9. doi: 10.1016/s0003-4975(98)00269-0
18. Cho S, Song IH, Yang HC, Jheon S. Prognostic factors of pulmonary metastasis from colorectal carcinoma. Interact Cardiovasc Thorac Surg. (2013) 17(2):303–7. doi: 10.1093/icvts/ivt164
19. Socola F, Nguyen DM, Ochoa RE, Rocha Lima CM, Hosein PJ. A cohort study evaluating the role of surgery for lung metastases from colorectal cancer. Anticancer Res. (2015) 35(6):3431–5
20. Hamaji M, Cassivi SD, Shen KR, Allen MS, Nichols FC, Deschamps C, et al. Is lymph node dissection required in pulmonary metastasectomy for colorectal adenocarcinoma? Ann Thorac Surg. (2012) 94(6):1796–800. doi: 10.1016/j.athoracsur.2012.04.049

ACKNOWLEDGMENTS
The authors thank Marcela Nuñez for the biostatistical analysis.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Carvajal, Facundo, Puerto, Carreño and Beltrán. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.